Addex Therapeutics and National Institute on Drug Abuse (NIDA) Enter Collaboration to Advance ADX71441 & ADX88178 in Drug Abuse and Addiction

Published: Nov 04, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a collaboration with the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) to evaluate the pharmacology of ADX71441, a GABAB receptor positive allosteric modulator (PAM), and ADX88178, an mGlu4 PAM in preclinical models of drug abuse and addiction. The collaboration will evaluate Addex drug candidates, ADX71441 and ADX88178 in a battery of preclinical models to study their potential as treatments for nicotine and cocaine addiction.

Help employers find you! Check out all the jobs and post your resume.

Back to news